Regulatory dendritic cells for immunotherapy in immunologic diseases

151Citations
Citations of this article
196Readers
Mendeley users who have this article in their library.

Abstract

We recognize well the abilities of dendritic cells to activate effector T cell (Teff cell) responses to an array of antigens and think of these cells in this context as pre-eminent antigen-presenting cells, but dendritic cells are also critical to the induction of immunologic tolerance. Herein, we review our knowledge on the different kinds of tolerogenic or regulatory dendritic cells that are present or can be induced in experimental settings and humans, how they operate, and the diseases in which they are effective, from allergic to autoimmune diseases and transplant tolerance. The primary conclusions that arise from these cumulative studies clearly indicate that the agent(s) used to induce the tolerogenic phenotype and the status of the dendritic cell at the time of induction influence not only the phenotype of the dendritic cell, but also that of the regulatory T cell responses that they in turn mobilize. For example, while many, if not most, types of induced regulatory dendritic cells lead CD4+ naïve or Teff cells to adopt a CD25+Foxp3+ Treg phenotype, exposure of Langerhans cells or dermal dendritic cells to vitamin D leads in one case to the downstream induction of CD25+Foxp3+ regulatory T cell responses, while in the other to Foxp3- type 1 regulatory T cells (Tr1) responses. Similarly, exposure of human immature versus semi-mature dendritic cells to IL-10 leads to distinct regulatory T cell outcomes. Thus, it should be possible to shape our dendritic cell immunotherapy approaches for selective induction of different types of T cell tolerance or to simultaneously induce multiple types of regulatory T cell responses. This may prove to be an important option as we target diseases in different anatomic compartments or with divergent pathologies in the clinic. Finally, we provide an overview of the use and potential use of these cells clinically, highlighting their potential as tools in an array of settings. © 2014 Gordon, Ma, Churchman, Gordon and Dawicki.

References Powered by Scopus

Immunobiology of dendritic cells

5835Citations
N/AReaders
Get full text

Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver

2377Citations
N/AReaders
Get full text

Recognition of microorganisms and activation of the immune response

2244Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Lung cancer immunotherapy: progress, pitfalls, and promises

432Citations
N/AReaders
Get full text

EAACI Allergen Immunotherapy User's Guide

239Citations
N/AReaders
Get full text

Tolerogenic dendritic cells for regulatory T cell induction in man

217Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Gordon, J. R., Ma, Y., Churchman, L., Gordon, S. A., & Dawicki, W. (2014). Regulatory dendritic cells for immunotherapy in immunologic diseases. Frontiers in Immunology. Frontiers Research Foundation. https://doi.org/10.3389/fimmu.2014.00007

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 84

62%

Researcher 38

28%

Professor / Associate Prof. 9

7%

Lecturer / Post doc 4

3%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 50

37%

Immunology and Microbiology 46

34%

Medicine and Dentistry 22

16%

Biochemistry, Genetics and Molecular Bi... 18

13%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
References: 1

Save time finding and organizing research with Mendeley

Sign up for free